FEMY

Femasys Inc

1.42

Nov 13 • 3:59 PM ET +0.02 (1.43%)

1.44

Aftermarket • 7:49 PM ET +0.02 (1.41%)

Healthcare Medical Instruments & Supplies USA Nano NASD

Nov 13, 7:45 PMFemasys Inc reports fiscal Q3 2026 results with non-GAAP EPS $-0.53 (+74% YoY) and revenue $404,600 (-45% YoY), beats EPS but misses revenue estimates

Peers: UTMD COO DARE IVF OGN TXMD NIVF PRGO SERA NTRA

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	11.89M
Enterprise Value	-6.86M
Income	-12.66M
Sales	1.97M
Book/sh	3.12
Cash/sh	2.86
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	54
IPO	Jun 18, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	6.04
P/B	0.45
P/C	0.50
P/FCF	-
EV/EBITDA	-
EV/Sales	-3.48
Quick Ratio	6.95
Current Ratio	8.67
Debt/Eq	0.19
LT Debt/Eq	0.16
Option/Short	No / Yes

EPS (ttm)	-3.10
EPS next Y	-2.12
EPS next Q	-0.51
EPS this Y	72.34%
EPS next Y	18.27%
EPS next 5Y	44.87%
EPS past 3/5Y	21.27% 4.34%
Sales past 3/5Y	23.88% 17.18%
EPS Y/Y TTM	73.27%
Sales Y/Y TTM	-4.21%
EPS Q/Q	74.23%
Sales Q/Q	-44.53%
Earnings	Nov 13 AMC
EPS/Sales Surpr.	12.40% -34.69%

Insider Own	3.43%
Insider Trans	17.07%
Inst Own	54.65%
Inst Trans	37.67%
ROA	-49.26%
ROE	-80.14%
ROIC	-40.27%
Gross Margin	19.71%
Oper. Margin	-929.87%
Profit Margin	-640.89%
SMA20	-1.85%
SMA50	-27.41%
SMA200	-74.56%
Trades

Shs Outstand	8.66M
Shs Float	8.09M
Short Float	0.61%
Short Ratio	0.07
Short Interest	0.05M
52W High	20.80 -93.17%
52W Low	1.25 13.15%
Volatility	9.70% 9.93%
ATR (14)	0.16
RSI (14)	39.84
Beta	-2.17
Rel Volume	0.08
Avg Volume	698.92K
Volume	52,899

Perf Week	3.65%
Perf Month	-18.16%
Perf Quarter	-34.26%
Perf Half Y	-80.09%
Perf YTD	-87.68%
Perf Year	-91.41%
Perf 3Y	-93.17%
Perf 5Y	-99.00%
Perf 10Y	-
Recom	1.00
Target Price	16.50
Prev Close	1.40
Price	1.42
Change %	1.43%

Consensus

Strong Buy

Avg. Price Target

$16.50

Implied Upside

+1,062.0%

Analysts1incl. previous ratings

Rating Distribution1 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 20, 2025	Initiated	LLaidlaw	Buy	$6.50	+357.7%

Nov-13-26 04:05PM	Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update (GlobeNewswire)
Oct-30-26 09:00AM	Femasys Appoints John Moorhead to Board of Directors (GlobeNewswire)
Oct-20-26 09:00AM	Femasys Partners with SandsRx Pharmacy to Support FemaSeed Fertility Portfolio Launch to OB/GYNs (GlobeNewswire)
Oct-14-26 09:00AM	Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control (GlobeNewswire) -11.36%
Oct-08-26 10:38AM	Femasys to Showcase FemaSeed Fertility Treatment at ASRM 2026 as Commercialization Strategy Expands (InvestorsHub)
09:00AM	Loading…
09:00AM	Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo (GlobeNewswire)
Sep-15-26 09:00AM	Femasys Advances OB/GYN Expansion with Adoption of FemaSeed Fertility Portfolio by Minnesota Women's Care (GlobeNewswire)
Sep-09-26 09:00AM	Femasys Partners with CapexMD to Expand Patient Access to FemaSeed Fertility Portfolio (GlobeNewswire) +5.60%
Aug-26-26 09:00AM	Femasys Partners with UNC Health to Introduce Its FemaSeed Fertility Portfolio Across Statewide OB/GYN Care Locations (GlobeNewswire)
Aug-19-26 12:01PM	FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology Retail Sees 500% Upside Potential (Stocktwits) +23.18%
10:37AM	Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc (InvestorsHub)
09:00AM	Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc (GlobeNewswire)
Aug-14-26 04:05PM	Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update (GlobeNewswire) -5.68%
Aug-12-26 09:00AM	Femasys Strengthens and Extends Global Patent Protection for FemBloc with First Issued Blended Polymer Patents (GlobeNewswire)
Aug-07-26 09:25AM	Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million (GlobeNewswire) -9.83%
09:00AM	Loading…
Jun-24-26 09:00AM	Femasys Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) -8.48%
May-13-26 09:00AM	Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG Catheter (GlobeNewswire)
May-08-26 04:05PM	Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update (GlobeNewswire) -5.98%
May-05-26 09:00AM	Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed Complete (GlobeNewswire) +7.42%
Apr-22-26 09:00AM	Femasys Launches FemaSeed Complete for OB/GYNs at ACOG 2026 (GlobeNewswire)
Apr-16-26 09:00AM	Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio (GlobeNewswire)
Apr-01-26 09:00AM	Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth (GlobeNewswire)
Mar-31-26 04:05PM	Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update (GlobeNewswire) +11.76%
Mar-18-26 09:00AM	Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors (GlobeNewswire)
Mar-10-26 09:00AM	Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment (GlobeNewswire)
Feb-27-26 05:26PM	Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.60%
Feb-26-26 09:00AM	Femasys Announces FemBloc Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access (GlobeNewswire)
Feb-23-26 09:00AM	Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination (GlobeNewswire)
Feb-03-26 09:15AM	Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products (GlobeNewswire)
Jan-14-26 09:00AM	Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement (GlobeNewswire) +17.81%
09:00AM	Loading…
Jan-13-26 09:00AM	Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed in Community-Based Care (GlobeNewswire)
Dec-18-25 09:15AM	Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device (GlobeNewswire)
Nov-25-25 09:15AM	PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment (Business Wire) +7.78%
Nov-14-25 04:01PM	Femasys Announces Third Quarter Financial Results for 2025 (GlobeNewswire) +8.58% -11.28%
Nov-10-25 09:00AM	Femasys Advances Global Growth with Second Partner Order for FemBloc in Europe (GlobeNewswire)
Nov-03-25 08:30AM	Femasys Secures FDA Approval to Advance Final FemBloc Trial Phase and $12 Million Financing, with Potential to Reach $58 Million (GlobeNewswire)
Oct-22-25 09:00AM	Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc Permanent Birth Control in Europe (GlobeNewswire) -9.57%
Oct-16-25 09:00AM	Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo (GlobeNewswire) +35.38%
Sep-25-25 09:00AM	Femasys Accelerates European Growth for FemBloc with Kebomed Partnership (GlobeNewswire)
Sep-23-25 09:20AM	Femasys partners with Medical Electronic Systems for FemSperm kit (TipRanks)
Sep-22-25 09:00AM	Femasys Partners with Medical Electronic Systems to Launch FemSperm Analysis Kit for use with FemaSeed (GlobeNewswire)
Sep-11-25 09:00AM	Femasys Expands FemSperm Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed (GlobeNewswire)
Sep-08-25 09:00AM	Femasys Secures Regulatory Approval for FemBloc Permanent Birth Control in New Zealand (GlobeNewswire)
Sep-02-25 09:00AM	Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios (GlobeNewswire) +12.62%
Aug-27-25 12:02PM	Femasys (FEMY) Falls 27% as Firm to Raise $8-Million from Share Sale (Insider Monkey)
Aug-25-25 11:44PM	Femasys Announces Pricing of $8.0 Million Underwritten Public Offering (GlobeNewswire) -9.79% -27.00%
Aug-21-25 09:00AM	Femasys Announces FemSperm Kit to Activate Gynecologists and Advance FemaSeed Fertility Platform (GlobeNewswire) -8.66%
Aug-20-25 09:00AM	Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control (GlobeNewswire) -7.38%
Aug-08-25 05:15PM	Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -13.16%
04:05PM	Femasys Announces Second Quarter Financial Results for 2025 (GlobeNewswire)
Aug-07-25 09:25AM	Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.33%
Aug-06-25 06:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
09:00AM	Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion (GlobeNewswire)
Jul-01-25 09:00AM	Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed for First-Line Infertility Treatment and FemVue Diagnostic (GlobeNewswire)
Jun-25-25 09:00AM	Femasys Announces Historic Milestone with European Approval of FemBloc, the First Non-Surgical Permanent Birth Control (GlobeNewswire) +10.71%
Jun-17-25 09:00AM	Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth (GlobeNewswire)
Jun-11-25 09:00AM	Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed in its More than 8 Locations (GlobeNewswire) +6.25%
May-30-25 08:00AM	Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million (GlobeNewswire) -13.73%
May-29-25 04:23PM	Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement (GlobeNewswire)
May-08-25 07:00PM	Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.83%
05:01PM	Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update (GlobeNewswire)
May-06-25 09:05AM	Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-01-25 05:15PM	BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates (Zacks)
Mar-27-25 10:10AM	Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -12.17%
09:00AM	Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update (GlobeNewswire)
Mar-20-25 11:06AM	Femasys price target raised to $15 from $12 at H.C. Wainwright (TipRanks)
Mar-19-25 09:20AM	Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations (GlobeNewswire)
Mar-18-25 03:30PM	Q1 Virtual Investor Summit: On-Demand Presentations Now Live (ACCESS Newswire)
09:00AM	Femasys Secures Distribution Partnerships for Commercialization of FemBloc in Spain (GlobeNewswire)
Mar-13-25 08:30AM	Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach (GlobeNewswire)
Feb-25-25 09:20AM	Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc Permanent Birth Control Clinical Trials (GlobeNewswire)
Feb-11-25 09:00AM	Femasys Announces UK Regulatory Approvals for FemaSeed for Female Infertility Treatment and Two Diagnostic Devices (GlobeNewswire) +7.76%
Feb-05-25 07:28AM	Femasys gains approvals for infertility and diagnostic products in Israel (Medical Device Network) +6.19%
Feb-04-25 09:00AM	Femasys Announces Israeli Regulatory Approvals for FemaSeed for Female Infertility Treatment and Two Diagnostic Devices (GlobeNewswire)
Jan-30-25 08:30AM	Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control (GlobeNewswire)
Jan-16-25 08:30AM	Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed for Female Infertility Treatment (GlobeNewswire)
Dec-03-24 09:00AM	Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed (GlobeNewswire)
Nov-26-24 08:30AM	Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed Infertility Treatment (GlobeNewswire)
Nov-12-24 09:45AM	Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -11.59%
08:30AM	Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update (GlobeNewswire)
Nov-07-24 08:30AM	Femasys to Exhibit at the Annual AAGL 2024 Global Conference (GlobeNewswire)
Nov-01-24 08:30AM	Femasys Announces Issued U.S. Patent Covering FemBloc Device for Female Permanent Birth Control (GlobeNewswire) -5.26%
Oct-30-24 09:00AM	Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed (GlobeNewswire)
Oct-10-24 08:30AM	Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program (GlobeNewswire)
Oct-08-24 08:30AM	Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-02-24 08:30AM	Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed Infertility Treatments (GlobeNewswire)
Sep-18-24 08:30AM	Femasys Announces Infertility Clinic Customers from Coast to Coast (GlobeNewswire)
Sep-11-24 08:30AM	Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed for over $1.3M in Spanish Market (GlobeNewswire) +7.48%
Sep-09-24 11:53AM	FDA clears FemChec for fallopian tube occlusion testing (Medical Device Network)
08:30AM	Femasys Inc. Receives U.S. FDA Clearance to Market FemChec , an Innovative Diagnostic Solution for Fallopian Tube Check (GlobeNewswire)
Sep-05-24 08:30AM	Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting (GlobeNewswire)
Sep-03-24 08:30AM	Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.84%
Aug-30-24 06:32AM	Femasys secures CE mark certification for FemVue MINI solution (Medical Device Network)
Aug-29-24 08:30AM	Femasys Announces CE Mark and Canadian Approval for FemVue MINI, a Fallopian Tube Assessment Solution (GlobeNewswire) +10.48%
Aug-27-24 08:30AM	Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters (GlobeNewswire)
Aug-08-24 09:45AM	Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -18.09%
08:30AM	Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update (GlobeNewswire)
Jun-27-24 08:30AM	Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam (GlobeNewswire) +10.58%
Jun-21-24 04:32AM	Femasys gains CE Mark approval for womens health products (Medical Device Network) -9.45%
Jun-20-24 08:30AM	Femasys Receives CE Mark Approval for Four of its Women's Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe (GlobeNewswire) +32.98%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mifek Jeffrey Gerald	Chief Clinical-Medical Affairs	Aug 07 '26	Buy	3.20	3,125	10,000	3,125	Aug 11 08:54 PM
Sipos Jeremy Alexander	Chief Technology Officer	Aug 07 '26	Buy	3.20	3,125	10,000	3,125	Aug 11 08:44 PM
Canning John Charles	Chief Operating Officer	Aug 07 '26	Buy	3.20	4,375	14,000	4,375	Aug 11 08:40 PM
Elefant Dov	Chief Financial Officer	Aug 07 '26	Buy	3.20	15,625	50,000	15,625	Aug 11 08:37 PM
Lee-Sepsick Kathy	Chief Executive Officer	Aug 07 '26	Buy	3.20	15,625	50,000	15,625	Aug 11 08:30 PM

Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

FounderMs. Kathy Lee-Sepsick M.B.A.

Chief Financial OfficerMr. Dov Elefant

Chief Operating OfficerMr. John Canning

Chief Technology OfficerMr. Jeremy Alexander Sipos M.S.

Chief Medical OfficerDr. James H. Liu M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

FEMY

Femasys Inc

Upgrade your Finviz experience

All the Features.
Half the Price.